methyl (R)-(-)-3-methyl-5-oxohexanoate | 89393-66-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (R)-(-)-3-methyl-5-oxohexanoate
• 英文别名: D-3-methyl-5-oxo-hexanoic acid methyl ester；D-3-Methyl-5-oxo-hexansaeure-methylester；methyl (3R)-3-methyl-5-oxohexanoate
• CAS: 89393-66-8
• 化学式: C₈H₁₄O₃
• 分子量: 158.197
• InChiKey: QIZFMIXTHKTRJG-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (R)-(-)-3-methyl-5-oxohexanoate 生成 DL-3-甲基-Γ-丁内酯
  参考文献：
  名称：

  KOGA, KEHNDZI;TOMIOKA, KIESI;YASUDA, KOSUKEH;TAKIGAVA, TEHTSUO

  摘要：

  DOI：
• 作为产物：
  描述：

  巴豆酸甲酯 在 臭氧 、 lithium diisopropyl amide 作用下， 以 二氯甲烷 为溶剂， 生成 methyl (R)-(-)-3-methyl-5-oxohexanoate
  参考文献：
  名称：

  Asymmetric synthesis of β-substituted δ-ketoesters via michael-additions of samp/ramp-hydrazones to α,β-unsaturated esters, virtually complete 1.6-asymmetric induction

  摘要：

  DOI：

  10.1016/s0040-4039(01)99823-5

文献信息

• TRANSESTERIFICATION REACTION BY MEANS OF IRON CATALYST
  申请人：KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

  公开号：US20170275241A1

  公开（公告）日：2017-09-28

  Provided is a catalyst for transesterification reactions, which contains an iron salen complex. Also provided is a method for producing an ester compound, which is characterized by carrying out a transesterification reaction between a starting material ester and a starting material alcohol with use of the catalyst.

  提供了一种用于酯交换反应的催化剂，其中包含铁Salen配合物。还提供了一种生产酯化合物的方法，其特点是利用该催化剂在起始物酯和起始物醇之间进行酯交换反应。
• Use of core 2 GlcNac-T inhibitors III for treating autoimmune diseases
  申请人：BTG International Limited

  公开号：EP2382979A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition is an autoimmune condition.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选定的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中所述病症为自身免疫性病症。
• Use of Core 2 GlcNac-T inhibitors III for treating vascular complications of diabetes
  申请人：BTG International Limited

  公开号：EP2382980A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition is selected from vascular complications of diabetes.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选定的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中所述病症选自糖尿病的血管并发症。
• Use of Core 2 GlcNac-T inhibitors III for the treatment of inflammatory conditions
  申请人：BTG International Limited

  公开号：EP2382981A2

  公开（公告）日：2011-11-02

  Treatments for conditions involving detrimental activity of the enzyme core 2 GlcNAc - T are provided using compounds of the formula I wherein R1 is H, -OH, C1-6 alkoxy, -NR5R6, or Sac 1; R2 is H, -OH, C1-6 alkoxy or Sac 2; R3 is H, -OH, C1-6 alkoxy or Sac 3; R4 is H, C1-6 alkyl, C1-6 hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl; R5 is H, C1-6 alkyl or C1-6 acyl; R6 is H, C1-6 alkyl or C1-6 acyl; Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties; and Z is a steroid moiety; or a pharmaceutically acceptable salt, ether or ester form thereof, wherein the condition to be treated is an inflammatory condition selected from ileitis, cholitis, cholecystitis, diverticulitis, gastritis, irritable bowel syndrome, inflammatory bowel disease, Lupus and ulcerative cholitis.

  使用式 I 的化合物可治疗涉及核心 2 GlcNAc - T 酶有害活性的病症。 其中 R1 是 H、-OH、C1-6 烷氧基、-NR5R6 或 Sac 1； R2 是 H、-OH、C1-6 烷氧基或 Sac 2； R3 是 H、-OH、C1-6 烷氧基或 Sac 3； R4 是 H、C1-6-烷基、C1-6-羟基烷基或 C1-6- 烷氧基-C1-6-烷基； R5 是 H、C1-6 烷基或 C1-6酰基； R6 是 H、C1-6 烷基或 C1-6 丙烯酸基； Sac 1 Sac 2 和 Sac 3 是独立选择的糖分子；以及 Z 是类固醇分子； 或其药学上可接受的盐、醚或酯形式，其中待治疗的病症是选自回肠炎、胆囊炎、胆囊炎、憩室炎、胃炎、肠易激综合征、炎症性肠病、红斑狼疮和溃疡性胆炎的炎症。
• Asymmetric Michael Addition of Malonate Anions to Prochiral Acceptors Catalyzed by <scp>l</scp>-Proline Rubidium Salt
  作者：Masahiko Yamaguchi、Tai Shiraishi、Masahiro Hirama

  DOI：10.1021/jo960216c

  日期：1996.1.1

  L-Proline rubidium salt catalyzes the asymmetric Michael addition of malonate anions to prochiral enones and enals. This method can be applied to a wide range of substrates to give adducts with a predictable absolute configuration: (S)-adducts from (E)-enones/enals and (R)-adducts from cyclic (Z)-enones. Both the secondary amine moiety and the carboxylate moiety are critical for the catalytic activity and asymmetric induction. Varying the countercation also affects the reaction course. High enantiomeric excesses were attained when di(tert-butyl) malonate was added to (E)-enones in the presence of CsF. The stereochemistry of the Michael reaction indicates that asymmetric induction takes place via enantioface discrimination involving the acceptor alpha-carbon atom rather than the beta-carbon atom.